Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06250582

Does Virtual Reality Improve Symptom Burden in Dialysis Patients?

The goal of this clinical trial is to investigate the use of virtual reality therapy in dialysis patients. The main question it aims to answer is: Does virtual reality improve symptom burden in dialysis patients and improve their mental wellbeing? Over a period of one month, one virtual reality therapy session of 30 minutes will be performed during each regular hemodialysis session. Since we will conduct a monocentric, crossover randomized controlled trial, the participants act as their own control group.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Zurich

Zurich, Canton of Zurich, 8091, Switzerland

Location status: Recruiting

Location contact

David Blum, Prof.Dr.med.

CONTACT

[email protected]

+41 43 253 37 42

About this study

Hemodialysis is a lifesaving therapy for patients with end stage kidney disease but comes with a high burden of physical and emotional symptoms that lower quality of life in dialysis patients. Dialysis mediated complications such as drops in blood pressure, nausea and muscle cramps results in refusal and a negative perception of this treatment. In dialysis patients, treatment-related burden results in deterioration in health related quality of life. During the past few years, Virtual reality (VR) has become more affordable and found its way into households as entertainment electronics but stepwise also into medicine. VR enables the user to view, interact and be immersed in a multisensory 3D virtual world. The aim of the current study is to reduce dialysis-related burden of symptoms by using virtual reality therapy during regular dialysis sessions and thereby improve quality of life among dialysis patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Older than 18 years;
  • in treatment with thrice-weekly hemodialysis sessions;
  • regular hemodialysis duration of three to five hours
  • having no visual impairment
  • having no acoustic deficit
  • patient must be capable of speaking and understanding German or English
  • no signs of cognitive impairment
  • patient oriented in time and space
  • being able to give informed consent as documented by signature

Exclusion criteria

  • diagnosis of epilepsy
  • current pregnancy

Treatment and study plan

virtual reality therapy

Other

A virtual reality therapy will be applied for 30 minutes. Patients will be wearing the glasses while lying in bed/chair during their regular dialysis session. Vital signs will be monitored repeatedly. At defined times, patients are asked to answer various questionnaires about their physical and mental health.

Primary outcomes

  1. Reduction of symptom burden of dialysis patients and improvement of their mental wellbeing

    Time frame: 10 weeks

    questionnaire

Secondary outcomes

  1. Evaluation of the effects of virtual reality therapy during hemodialysis on heart rate

    Time frame: 10 weeks

    Heart rate (beats per minute)

  2. Evaluation of the effects of virtual reality therapy during hemodialysis on blood pressure

    Time frame: 10 weeks

    Blood pressure (mm Hg)

  3. To assess the acceptability and appropriateness of using VRT during hemodialysis from the perspectives of patients

    Time frame: 10 weeks

    questionnaire

  4. To assess the acceptability and appropriateness of using VRT during hemodialysis from the perspectives of clinical staff

    Time frame: 10 weeks

    questionnaire

  5. To test the internal consistency of the ESAS-r: Renal Score

    Time frame: 10 weeks

    Cronbach's alpha

Study contacts

Contact information is provided by the study sponsor or research team.

David Blum, Prof.

CONTACT

[email protected]

+41432533742

STefan Pelz, Dr. med.

CONTACT

[email protected]

+41442553535

Sponsors and collaborators

Lead sponsor

David Blum

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Feb 9, 2024
Registry last updated
Apr 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.